Article type
Abstract
"Background: The process of Health Technology Assessment involves clinical, social, organizational and economic aspects, and is always based on the evaluation and synthesis of available evidence. In Brazil, this process can result in the incorporation in the public health system of medicines that must be available for the population within 180 days , in accordance with current legislation.
Objectives: analyze the effective offer of a group of 60 medicines incorporated in brazilian public health system between 2012 and 2016 for the treatment of chronic and rare diseases and hepatitis.
Method: Retrospective analytical study, using real-world data of drug dispensations that occurred between 2012 and 2017 in the brazilian public health system. The offer period was defined as the date of the first dispensation.
Results: 1,198 records of the first dispensing were computed between 2012 e 2017, with only 12% (n = 144/1,198) achieved the deadline and the average delay of those who did not meet the deadline was 14 months.
Conclusion: The deadline was outside the established limit, evidencing the importance of using real-world data to improve processes related to the supply of incorporated medicines, as well as reevaluate the established rule in view of the profile presented and necessary procedures related to the acquisition and dispensing processes. This delay in the offer of incorporated medicines has a direct impact on patients' health, because medicines play an important role in protecting, maintaining and restoring people's health.
"
Objectives: analyze the effective offer of a group of 60 medicines incorporated in brazilian public health system between 2012 and 2016 for the treatment of chronic and rare diseases and hepatitis.
Method: Retrospective analytical study, using real-world data of drug dispensations that occurred between 2012 and 2017 in the brazilian public health system. The offer period was defined as the date of the first dispensation.
Results: 1,198 records of the first dispensing were computed between 2012 e 2017, with only 12% (n = 144/1,198) achieved the deadline and the average delay of those who did not meet the deadline was 14 months.
Conclusion: The deadline was outside the established limit, evidencing the importance of using real-world data to improve processes related to the supply of incorporated medicines, as well as reevaluate the established rule in view of the profile presented and necessary procedures related to the acquisition and dispensing processes. This delay in the offer of incorporated medicines has a direct impact on patients' health, because medicines play an important role in protecting, maintaining and restoring people's health.
"